Research Article
Treatment with Molgramostim (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor, Rhugm-Csf, Mielogen) and Lenograstim (Granulocyte-Colony Stimulating Factor) Improves Experimental Colitis in Rats
Table 2
Pathology results divided in three categories, 0: normal mucosa, 1: colitis in remission, 2: active colitis, according to Geboes histological score.
| | Groups | Category 0 (normal mucosa) | Category 1 (colitis in remission) | Category 2 (active colitis) | Pearson’s Χ2 test |
| | 1 (Colitis, 15 days, control group) | 20% (2/10) | 30% (3/10) | 50% (5/10) | | | 2 (Colitis, 30 days, control group) | 50% (5/10) | 30% (3/10) | 20% (2/10) | | | 3 (Granulocyte) | 67% (4/6) | 33% (2/6) | 0% (0/6) | (vs group 1) vs group 2 | | 4 (Granulocyte) | 83% (5/6) | 17% (1/6) | 0% (0/6) | (vs group 1) vs group 2 | | | | | | | 5 (Granulocyte) | 83% (5/6) | 17% (1/6) | 0% (0/6) | (vs group 1) vs group 2 | | 6 (Mielogen) | 50% (3/6) | 17% (1/6) | 33% (2/6) | (vs group 1) vs group 2 | | 7 (Mielogen) | 0% (0/6) | 50% (3/6) | 50% (3/6) | NS vs group 2 | | 8 (Mielogen) | 17% (1/6) | 0% (0/6) | 83% (5/6) | NS vs group 2 | | 9 (Prednizolone) | 33% (2/6) | 50% (3/6) | 17% (1/6) | (vs group 1) vs group 2 |
|
|
